
Quarterly report 2023-Q2
added 08-03-2023
Axcella Health Net Debt 2011-2025 | AXLA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Axcella Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.5 M | -46.4 M | -67.2 M | -54.9 M | -27.3 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.5 M | -67.2 M | -38.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.79 | - | $ 795 M | ||
|
Aclaris Therapeutics
ACRS
|
-22 M | $ 3.04 | - | $ 235 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 1.17 | - | $ 6.38 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 212.81 | 1.71 % | $ 5 B | ||
|
Aptevo Therapeutics
APVO
|
-3.28 M | $ 0.93 | - | $ 257 K | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.1 | 0.16 % | $ 7.46 B | ||
|
BioVie
BIVI
|
-17.2 M | $ 1.27 | - | $ 1.88 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 95.03 | - | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 26.81 | 1.36 % | $ 1.3 B | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 0.18 | 3.03 % | $ 392 M | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 9.48 | - | $ 139 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | ||
|
Axon Enterprise
AXON
|
-404 M | $ 591.15 | - | $ 44.8 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.53 | -0.39 % | $ 15.9 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 92.45 | - | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 12.37 | 2.06 % | $ 814 M | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 9.0 | - | $ 1.48 B | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 26.83 | - | $ 1.73 M | ||
|
Cellectar Biosciences
CLRB
|
-9.01 M | $ 2.76 | - | $ 33.7 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 10.81 | - | $ 699 M | ||
|
Biogen
BIIB
|
4.01 B | $ 176.33 | - | $ 25.7 B | ||
|
Cerevel Therapeutics Holdings
CERE
|
-33.6 M | - | - | $ 7.29 B |